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MANAGING VARIANT DISCREPANCY IN HEREDITARY CANCER:
CLINICAL PRACTICE, BARRIERS, AND DESIRED RESOURCES
Ellen Hope Zirkelbach, BS
Advisory Professor: Syed S. Hashmi, MD, MPH, Ph.D.
Variants are changes in the DNA whose phenotypic effects may or may not be
definitively understood. Because variant interpretation is a complex process,
sources sometimes disagree on the classification of a variant, which is called a
variant discrepancy. This study aimed to determine the practice of genetic
counselors regarding variant discrepancies and to identify the barriers to
counseling a variant discrepancy in hereditary cancer genetic testing. This
investigation was unique because it was the first to address variant
discrepancies from a clinical point of view. An electronic survey was sent to
genetic counselors in the NSGC Cancer Special Interest Group. The vast
majority of counselors (93%) had seen a variant discrepancy in practice. The
most commonly selected barriers to counseling a variant discrepancy were lack
of data sharing (90%) and lack of a central database (76%). Most counselors
responded that the ideal database would be owned by a non-profit (59%) and
obtain information directly from laboratories (91%). When asked how they
approached counseling sessions involving variant discrepancies, the free
responses emphasized that counselors consider family history and
psychosocial concerns, showing that genetic counselors tailored the session to
each individual. Variant discrepancies are an ongoing concern for clinical
cancer genetic counselors, as demonstrated by the fact that counselors desired
further resources to aid in addressing variant discrepancies, including a
centralized database (89%), guidelines from a major organization (88%),
continuing education about the issue (74%) and functional studies (58%).
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INTRODUCTION
Evolving technologies have made it possible to examine the genome more
thoroughly than ever before. With these technologies, such as next generation
sequencing (NGS), challenges have arisen, including an increased need for variant
annotation and interpretation. Variants are changes in the DNA whose phenotypic
effects may or may not be definitively understood. For example, a variant may be found
that is known to cause an increased lifetime risk of cancer. Alternatively, a variant may
not be well understood, making it difficult to predict if it affects the lifetime risk of cancer
for the patient.
The previously mentioned NGS technology led to the development of a style of
genetic analysis called panel testing, which first became available in 2012 in cancer
genetics (Kurian et al., 2014). Many providers are turning to panel testing using NGS
since it is a cost-effective way to test many genes at once (Gallego et al., 2015). It has
been shown that the number of variants detected increases with the number of genes
sequenced (Lincoln et al., 2015). Therefore, the use of panel testing increases the
chance of discovering variants in genes associated with greater risk of cancer. In fact,
when 29 genes were sequenced in 1062 people, 41% had at least one variant and
11.4% had two or more variants (Lincoln et al., 2015). When 20,000 genes were
analyzed using whole exome sequencing (WES), variants of uncertain clinical
significance (VUS) were found in 95% of the study population (Maxwell et al., 2016). The
increasing rate of variant discovery has brought to light the importance of understanding
the effects of these gene changes.
When a variant is identified, its pathogenicity must be determined. In the 2015
Standards and Guidelines for the Interpretation of Sequence Variants, the American
College of Medical Genetics and Genomics (ACMG) recommended a 5-tiered system for
indicating pathogenicity: pathogenic (P), likely pathogenic (LP), variant of uncertain
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significance (VUS), likely benign (LB), and benign (B) (Richards et al., 2015). According
to these guidelines, laboratory classification of a variant should be based on multiple
lines of evidence, including population data, disease databases, segregation data,
scientific and medical literature, and in silico predictors (Richards et al., 2015). Some
experts attest that the most useful sources of information include allele frequency,
conservation data, co-segregation, and the mutation type (Amendola et al., 2015).
Population data can be found in databases such as the Exome Aggregation Consortium
(ExAC), 1000 Genomes, and the Exome Variant Server (EVS) (Richards et al., 2015).
From these databases, the prevalence of the allele in the population can be ascertained.
In general, the more rare the allele, the more likely it is to be pathogenic. Conservation
data can be found through Genomic Evolutionary Rate Profiling (GERP) and Combined
Annotation Dependent Depletion (CADD). The scores obtained through these services
indicate similarity between species. A lower CADD or GERP score means less
conservation between species, which is considered less likely to be pathogenic. Cosegregation, another tool for analyzing variants, can determine if a variant tracks with the
phenotype within a family. If the variant is present in family members with a disorder, it
cannot be ruled out as benign. Lastly, certain mutation types are associated with an
increased risk for pathogenicity. These include truncation of the gene, which implies an
abbreviated protein product, and a de novo condition occurring with a de novo variant,
which means both the condition and the gene change are new to the proband
(Amendola et al., 2015). Based on the information obtained from many sources, the
pathogenicity of a variant can be estimated, with varying degrees of certainty.
Once pathogenicity has been gauged, clinicians, including oncologists and genetic
counselors, must determine the clinical utility of the results. The ACMG states that
variants classified as either pathogenic or likely pathogenic are clinically actionable as
the terms imply a greater than 90% certainty that the variant in question is truly disease-
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causing (Richards et al., 2015). In such circumstances, management decisions can be
made based on pathogenicity, including prophylactic surgery and increased surveillance
for tumors. This idea is oversimplified, however, because the classification of variants is
not always straightforward. It has been shown that sources are not always concordant in
variant interpretation. For example, one laboratory may call a variant a VUS, while
another classifies it as likely pathogenic. Differences between laboratories may be due
to varying testing techniques, such as use of unlike cell lines or different assays
(Karbassi et al., 2016). The differences may also be due to discrepancies in variant
analysis, such as weighing evidence differently and setting varying thresholds for
pathogenicity. Another source of discrepancies may be that some researchers have
access to information that others do not. For example, one laboratory may have an
internal database of test results that are not shared with other laboratories (Amendola et
al., 2015).
Many previous studies have analyzed the frequency of variant discrepancies. When
nine Clinical Sequencing Exploratory Research (CSER) laboratories analyzed 97
variants, the classification was concordant between all laboratories in only 19% of cases
(Amendola et al., 2016). This number, however, may not be applicable to the clinical
genetic counselor since it is very unlikely that a patient would be tested at nine different
laboratories. Other more recent studies comparing annotations found in the ClinVar
database to those from commercial genetic testing laboratories have found an 11.7% to
26.7% rate of discordant variant classifications (Gradishar et al., 2017, Harrison et al.,
2017).
In order to analyze the prevalence of discordant classification in cancer genes
specifically, one study looked at agreement between databases for variants found in
their subjects via WES. Classifications were discordant in 16% of cases involving an
autosomal dominant cancer gene and 23% of cases involving an autosomal recessive
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cancer gene. There was a 4% rate of disagreement in clinical actionability for autosomal
dominant conditions, and a 9% rate for autosomal recessive. The same study found a
17% discrepancy rate for all cancer and non-cancer genes, and an overall rate of 4% for
disagreement on clinical actionability (Maxwell et al., 2015). Another study found that
26% of cancer variants found via recruitment into the Prospective Registry of Multiplex
Testing (PROMPT) had conflicting interpretations when compared to the ClinVar
database. In addition, 11% of variants had classifications that differed in clinical
actionability (Balmaña et al., 2016). Having up to 26% discordance in variant calling
implies an issue for clinicians in a cancer setting, who may receive different
classifications depending on the source reporting the result. This is especially troubling
in up to 11% of cases when the classification provided by one source implies clinical
actionability, while the classification from another source does not.
Because variant classifications can differ between sources, clinicians may have
difficulty applying discrepant variant results in a clinical setting. This study aims to
identify the strategies that clinical genetic counselors use to understand variant results,
to determine current counseling practice when there is a discordant result, and to
understand the barriers to counseling when there is a variant discrepancy in hereditary
cancer testing. The results may inform future guidelines for clinical application of
inconsistent variant annotation.
METHODS
Study Population
This study surveyed practicing cancer genetic counselors, specifically members of
the National Society of Genetic Counselors (NSGC) Cancer Special Interest Group
(SIG). An email was sent to Cancer SIG members explaining the basis of the study and
inviting them to complete the survey. Participation in the survey constituted consent to
the study, and counselors could opt to discontinue at any point in the survey. The
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inclusion criteria consisted of, 1; being a board certified or board eligible genetic
counselor working primarily in oncology, 2; spending more than 50% of their time in a
clinical setting, and 3; having attended an accredited genetic counseling master’s
program. These criteria excluded participants who had different experience and
expertise than required for this study. Student members of the SIG were also excluded.
Survey
The survey was created by the authors using Qualtrics software (2015) available
through the University of Texas Health Science Center at Houston. It was distributed via
email to members of the NSGC Cancer SIG in June 2016. Two reminder emails were
sent in July and August 2016. The survey was closed on August 31, 2016. The survey
took approximately 15-20 minutes for each participant to complete, and all answers were
anonymous.
The survey was a semi-structured questionnaire with 32 questions. There were 7
demographic questions that collected information about schooling and work setting. The
next section evaluated the counselor’s strategies for assessing variant results. In this
section, participants were asked questions about researching variants, including the
lines of evidence they used and how often they researched variants independently.
Counselors were then asked about their current counseling practice regarding variant
discrepancies, including how often they identified a variant discrepancy and how they
managed them in a clinical setting. There were two scenarios involving discovery of
variant discrepancies, followed by questions about how participants would handle these
situations. Lastly, there were questions regarding barriers to counseling when there are
discordant variant results. At the end of the survey, the counselors had the option to
input their email address to enter a drawing for a gift card. All research protocols met the
requirements of the University of Texas Health Committee for the Protection of Human
Subjects, and this study was assigned approval number HSC-MS-16-0436.
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Statistics
STATA 14 software was used to analyze statistics (StataCorp, 2015). Primary
outcomes included descriptive analyses. Results were reported as frequencies with
percentages. Secondary explorative analysis was performed, using Fisher exact tests or
t-tests based on the nature of the data, to compare differences between groups. All
comparative tests were considered significant at type I error rate of 5%. Free text
responses were analyzed for similarities.
RESULTS
Demographics
There were 281 responses to the survey, which represented 33% of the largest
mailing to 849 counselors. Twenty-five respondents did not complete the demographic
information and therefore were excluded from the analysis. There were 24 respondents
who met exclusion criteria, including current students and genetic counselors that did not
work primarily in a clinical oncology setting. This left a total of 224 responses that were
included in analysis. Of these, 60 (27%) were partially complete, and the answered
questions were included in analysis. The demographic information of the respondents is
reported in table 1.
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Table 1: Demographics
Number of Respondents
Percentage of Respondents
Year graduated from a genetic counseling master’s program
1971-1979
2
1980-1989
15
1990-1999
23
2000-2009
49
2010-2016
135
Experience in cancer genetics in number of years

1
7
10
22
60

0 to 5
145
5+ to 10
39
10+ to 15
21
15+ to 20
12
20+
7
Specialties counseled regularly
Pediatric
34
Breast
214
Gynecological
211
Endocrine
105
Gastrointestinal
214
Other*
12
Licensure available in participant’s state

65
18
9
5
3
15
96
95
47
96
5

Yes
No
Unsure

102
45
120
54
1
1
*Other responses: Nine counselors indicated that they counsel all specialties
(4%). One counselor indicated each of the following: “prostate” (1%), “leukemia” (1%),
and “head, neck, renal, CNS” (1%).
Strategies for Assessing Variant Results
The genetic counselors were asked a series of questions about how they approach
a non-discrepant variant result provided by a laboratory. A large majority, 178 (96%) of
counselors indicated that they conduct their own research on genetic testing results that
report a variant. The most common line of evidence used in research was disease
databases, with 148 counselors (83%) indicating that they use them “always” or “most of
the time”. Other commonly used lines of evidence were mutation type, with 94 (53%)
“always” or “most of the time” responses, and conducting a primary literature search,
with 87 (49%) “always” or “most of the time” responses. One line of evidence that was
less commonly used was functional studies, with 64 (36%) responses. Participants also
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ranked the lines of evidence that were most informative when researching variants.
Counselors were most likely to use the lines of evidence that they found the most
informative (p=0.01 for mutation type, p<0.0001 for all other lines of evidence).
To further explore the attitudes of counselors about variant results, they were asked
if their confidence in the classification of a single variant depended on the laboratory
providing it. Of 213 respondents, 178 (83%) of counselors affirmed that their confidence
does depend on the performing laboratory. To clarify, one respondent stated, “Not all
labs - or classification systems - are created equally. Whichever lab was ‘better’…is the
classification I would use for medical management”.
Current Variant Discrepancy Counseling Practice
Of 180 participants, 167 (93%) had seen a variant discrepancy in practice and 111
(62%) had come across a discrepancy on 3 or more occasions in the last 3 years. A total
of 143 (78%) counselors found a discrepancy by searching the variant in a disease
database. Eighty-five (46%), counselors indicated they discovered a discrepancy by
using different laboratories to test relatives, 73 (40%) indicated testing two unrelated
patients at different laboratories, and 29 (16%) indicated testing one patient at two
different laboratories.
Those that indicated they refer to databases “always” or “most of the time” when
researching variants were more likely to discover a discrepancy in a database
(p<0.0001). However, this same group was not statistically more or less likely to discover
discrepancies overall than those who refer to disease databases less often (p=0.518).
There was also no statistical difference in the likelihood of identifying a variant
discrepancy based on the type of testing most frequently ordered (p=0.254). Of our 213
respondents, 186 indicated that they order panel testing most often (87%), 4 indicated
that they order syndrome-specific testing most often (2%), and 23 indicated that they
order the two about equally (11%).
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Of 181 counselors, 98 (54%) reported taking 1-15 minutes to research a nondiscrepant variant result. When asked how long it takes to research a discrepant variant
with discordant classifications, 40 (24%) counselors indicated that it takes 46-60
minutes, 39 (23%) counselors selected 16-30 minutes, and 31 (19%) selected 31-45
minutes. There was a significant difference in the time spent researching a nondiscrepant variant versus a discrepant variant (p=0.001), with the majority of counselors
spending more time researching a variant discrepancy than a non-discrepant variant
(Figure 1). Of 160 respondents, 125 (78%) spent more time following up on a
discrepancy than researching a single variant, and 4 (3%) spent less time. A total of 52
(33%) counselors spent 45 minutes or more of extra time researching a discrepancy
compared to researching a single variant. The amount of time a counselor spent
following up on a discrepancy was not dependent on the number of discrepancies they
had previously discovered (p= 0.482).
Figure 1
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Scenarios were utilized to assess how respondents approach counseling sessions
involving variant discrepancies. In scenario A, a variant in Hereditary Breast and Ovarian
Cancer (HBOC) was classified by one laboratory as a VUS and by another as LP. Most
counselors indicated that they would explain both classifications, explain how each
classification was reached, emphasize that they are not the same, and discuss clinical
management for each. In scenario B, a variant in a gene associated with Lynch
Syndrome was classified by one laboratory as a VUS and by another other as LP. The
same four responses were selected most often for this question (figure 2). For the
majority of responses, those that selected a specific approach for the discrepancy in
scenario A involving HBOC were statistically more likely to choose that same approach
for the discrepancy in scenario B involving Lynch Syndrome. This is true for the following
responses: explain both (p=0.015), explain how each classification was reached
(p<0.0001), explain only VUS (p<0.0001), emphasize they are not the same (p<0.0001),
and discuss clinical management for each (p<0.0001).
Figure 2
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In scenario B, participants were also asked to select approaches to a counseling
session involving a variant in a gene associated with Lynch syndrome that is classified
as LP by one laboratory and P by another laboratory. Counselors were likely to respond
similarly to this question as to the previous question in scenario B, mentioned above,
where the variant is classified as LP and VUS (figure 3). This was the case for the
following responses: explain both (p=0.014), explain how each classification was
reached (p<0.0001), emphasize they are not the same (p=0.002), and discuss clinical
management for each (p=0.032). In general, more counselors chose to emphasize that
the classifications were not the same, with 121 (73%) respondents, and to discuss
clinical management for each, with 148 (90%) respondents, when comparing LP and
VUS. This is compared to 43 (26%) that chose to emphasize that the two classifications
were not the same and 60 (36%) that chose to discuss clinical management when
comparing LP and P (figure 3).

Figure 3
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Both scenarios allowed counselors to write “other” responses to the questions.
Many of these responses emphasized the importance of family history in deciding how to
approach a counseling session involving a discrepancy and how to manage the patient’s
care. For example, a respondent clarified that they “discuss the result in the context of
family history and whether prophylactic surgery could be recommended based on family
history alone.” The free responses also pointed out a focus on psychosocial support for
the patient. One counselor explained that they “discuss psychosocial aspects of having
discrepant test results and how that has impacted the patient.”
Barriers to Counseling
When asked to select barriers to the genetic counseling process regarding variant
discrepancies, 162 of 164 (99%) counselors selected at least one barrier. The most
frequently selected barrier with 147 responses was lack of data sharing (90%), followed
by 118 for lack of a central database (72%), 94 for lack of educational resources (60%),
and 88 for legal liability for clinicians and laboratories (54%).
Participants were asked to indicate who should ideally input information into a
centralized database, and 150 (95%) selected laboratories only or a combination of
laboratories and another source. No participants chose patients as the sole source of
information for a centralized database. A total of 96 respondents (59%) indicated that a
non-profit should own such a database. Forty-four counselors (27%) chose government
as the ideal owner of a centralized database.
Of 164 respondents, 115 indicated that they are concerned about legal liability
when it comes to variant discrepancies (70%). Licensed genetic counselors were
statistically more likely to indicate that they were concerned about legal liability than
those that are not licensed (p=0.004). However, there is no statistical difference in the
time that licensed and unlicensed counselors spend following up on variant
discrepancies (p=0.203). In addition, there was no difference in follow-up time between
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counselors who are concerned about legal liability and those that are not concerned
about legal liability (p=0.205).
Lastly, counselors chose resources that would help in counseling when they come
across a discrepancy (figure 4). The most common response selected by 148 (89%)
counselors was additional support from the laboratories involved with the discrepancy,
followed by 145 (88%) that chose practice guidelines from a major society/organization,
121 (74%) that chose continuing education opportunities, and 95 (58%) that chose
functional studies.
Figure 4

DISCUSSION
Frequency and Time Considerations
Clinical cancer genetic counselors should expect to come across the issue of
variant discrepancies in practice, given that 93% of respondents saw at least one
discrepancy in clinic. There was no difference in the number of discrepancies discovered
by those who order panel testing, syndrome-specific testing, or both about equally. This
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shows that cancer genetic counselors do not avoid encountering variant discrepancies
by ordering syndrome-specific panels.
Most respondents to this survey discovered an average of one discrepancy per
year, which is less prevalent than the 16-26% frequency of discrepancies in genes
associated with cancer cited in the literature (Balmaña et al., 2016, Maxwell et al., 2015).
Some previous studies, however, were looking at results that included many more genes
that the typical cancer panel, which today contains anywhere from 2 to 80 genes.
Studies show the more genes tested, the more likely there will be a variant found
(Lincoln et al., 2015, Maxwell et al., 2016). Therefore, it is not surprising that the
previous studies using WES found more discrepancies. It is important to note that the
research in cancer genetics is constantly being updated, so it is likely that more genes
will be gradually added to cancer panels and could increase the rate at which counselors
see discrepancies in the future. Another reason that this study may have found a lower
rate of discrepancies is that counselors ordering hereditary cancer testing may not
research every result they get. Though 96% of our study population indicated
researching variant results independently, it is possible certain classifications are more
likely to trigger further research, particularly if there is suspicion that the result may not
be appropriate for a patient’s clinical presentation or family history. If so, some
discrepancies may not be discovered.
Researching a discrepant variant was more time-consuming than researching a
non-discrepant variant. In fact, a third of counselors (33%) said they spend over 45
minutes researching a variant discrepancy. This is concerning because it consumes the
genetic counselor’s valuable clinic time. The time that counselors spent on a variant
discrepancy was not dependent on the number of discrepancies seen, licensure status,
or concern about legal liability. The fact that time spent was not dependent on how many
times they had seen discrepancies demonstrates that prior experience did not impact the
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amount of research time needed. None of these influenced the amount of time spent
researching a discrepancy, so there must be some other factor that drove the
differences between respondents that was not addressed in this survey.
Databases and Barriers to Counseling
The vast majority of respondents (96%) conducted their own independent
assessment on variants using available resources, including the 87% of counselors who
used disease databases. Disease databases were a widely utilized resource for
counselors when researching variants, and our respondents reported this is the most
frequently used line of evidence. This could be because many databases with
information about variants are readily accessible online, such as the disease databases
OMIM and ClinVar (Richards et al., 2015). Survey participants also reported that disease
databases were the most common way to discover a variant discrepancy. However,
those that refer to disease databases more often were not more likely to discover
discrepancies than counselors who used them less often. This shows that counselors
that did not use databases were not avoiding discovery of discrepancies. Other methods
of discovery, in order from most commonly selected to least, were using different
laboratories to test relatives, discovering the same variant in two patients tested at
different laboratories, and testing one patient at two laboratories.
Our study demonstrates that very few counselors are satisfied with resources
currently available to evaluate variant discrepancies given that a majority (99%) of
respondents selected at least one barrier. The most commonly selected barrier was lack
of data sharing followed by lack of a central database. Many obstacles would need to be
addressed in order to overcome lack of data sharing and create a central database. One
of these obstacles is curation. This includes the responsibility of updating the information
and ensuring common standardized nomenclature. Furthermore, some may feel that
sharing data means that others can make monetary gain from their work (Savage,
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2017). In addition, current databases have limited amount of phenotypic information
available about the patient with the variant, making it difficult to know if the variant is
clinically significant (Johnston et al., 2013).
Despite these obstacles, there are efforts underway to help reconcile the deficit of a
central database. One example is the Prospective Registry of Multiplex Testing
(PROMPT), which allows patients to self-enroll by inputting their panel testing results.
This registry allows data sharing through patient input and allows comparison of variant
classifications (Balmaña et al., 2016). Another database, BRCAShare, gathers
information about variants in the BRCA1 and BRCA2 genes. The data is obtained from
the Universal Mutation Database owned by the French Unicancer Genetic Group, along
with data from two commercial testing laboratories. This effort combines academic and
commercial knowledge into a central database (Rehm et al., 2015). However,
BRCAShare only gathers information for two of the many known cancer genes, so much
more is needed in the ideal database. There are other available resources, including
ClinVar, which is an initiative from the National Institute of Health that gathers
information about variants associated with many diseases including cancer, and GENIE,
which is an effort from the American Association for Cancer Research that gathers
patient information and genomic results (Savage, 2017).
This study clarified the ideal source for inputting data into databases and the ideal
owner of a centralized database. The majority of counselors (95%) indicated that the
laboratory alone or the laboratory combined with another source should input variant
data into a centralized database. Most survey participants (59%) indicated that a nonprofit should own such a database and about a quarter (27%) of respondents selected
government as the ideal owner. Based on these responses, counselors desire that
laboratories input information into a central database that is owned by a non-profit
organization without a potential conflict of interest.
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Approaching the Counseling Session
When it comes to patient care involving variant discrepancies, counselors were
consistent in their approach regardless of the hereditary cancer syndrome involved.
Additionally, counselors were statistically likely to choose the same approaches to the
session whether or not there was a difference in clinical actionability of the
classifications. When there was a discrepancy in actionability, counselors were more
likely by percentage to emphasize that the classifications were not the same and to
discuss management based on each classification.
The free response field after each scenario indicated that many counselors tailored
the session to the individual patient based on the personal and/or family history of
cancer, rather than tailoring the session to the syndrome involved or the clinical
actionability of the result. Genetic counselors are able to tailor recommendations by
synthesizing information from test results, personal history, and family history, which
allows them to provide patients a personalized risk assessment. When treatment and
management options are discussed in the context of the individual, there is an increase
in the quality of care. Other free responses focused on psychosocial support. This type
of support is unique to genetic counselors in the context of genetic testing. The fact that
respondents were able to tailor their session to the individual patient may be useful for
informing counselors who are deciding how to approach a discrepancy and for informing
future practice guidelines on variant discrepancies. Specifically that patient care requires
individualization based on test results, personal history, family history, and psychosocial
situation.
Laboratories and Other Resources
Most counselors (83%) indicated that their confidence in a classification depends
on the laboratory providing it. Furthermore, additional support from the laboratories was
the most commonly selected resource that would help with addressing a variant
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discrepancy. These results indicated that interaction with the laboratory and which
specific laboratory is involved were important factors when dealing with variant
discrepancies. It also demonstrates the need for laboratories to provide support and
resources to providers regarding hereditary cancer testing as well as the responsibilities
laboratories have for communicating effectively with providers.
Following additional support from the laboratories involved, practice guidelines from
a major society/organization and continuing education opportunities were the second
and third most commonly selected resources, respectively. Currently, no guidelines
address discrepancies in variant classification, including those from the National
Comprehensive Cancer Network, American Society of Clinical Oncology, National
Society of Genetic Counselors, or the guidelines on interpretation of sequence variants
from the American College of Medical Genetics.
Furthermore, more than half (58%) of counselors chose functional studies as a
resource that could help with addressing a variant discrepancy. Functional studies allow
creation of the gene product from the DNA sequence. By creating the product from the
sequence with the variant, researchers can ascertain if the DNA change maintains
functionality of the gene. Functional studies were not widely utilized as a line of evidence
for researching variants, which could be because this type of data was not available for
many variants. This lack of availability could be due to the fact that they require a high
monetary and temporal investment (Simpson et al., 2017). Despite these challenges,
functional studies are known to be valuable for interpretation of variants, and performing
these studies is of importance to advance knowledge of hereditary cancer (Amendola et
al., 2015, Imyanitov et al., 2004, Richards et al., 2015). Fortunately, some genetic testing
laboratories have started performing functional studies ("Myriad myChoiceTM HRD
Technical Specifications.").
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Limitations
The respondents to this survey may represent a skewed sample due to selection
bias. Genetic counselors who have seen a variant discrepancy in practice or who
conduct their own research on variants may have been more likely to take the survey.
The survey itself was created by the investigators and was not validated.
Additionally, some responses had a small sample size, which limited the ability for
statistical comparisons between groups. For example, there were a small number of
respondents that order syndrome-specific testing most often (n=4, 2%). This made
comparisons between that group and the group that ordered panel testing most often
(n=186, 87%) less robust.
Future Directions
These results call for additional resources to aid counselors in addressing variant
discrepancies, including creation of a centralized database, additional support from
laboratories, practice guidelines from a professional organization, continuing education
on discrepancies, and functional studies. While respondents noted that having a central
database owned by a non-profit with variant information from testing laboratories was
desirable, additional research could help further define the ideal disease database and
inform the creation of such a resource. A similar study could be conducted in the future
to learn if counselors indeed see an increase in the number of variant discrepancies in
practice over time.
Conclusions
This investigation was unique because it was the first to address variant
discrepancies from a clinical point of view. Cancer genetic counselors discovered
fewer variant discrepancies in practice than suggested in previous literature, but
addressing this issue is a concern for the genetic counseling profession since the vast
majority of counselors have seen discrepancies in practice. Genetic counselors desire
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further resources to aid in addressing variant discrepancies, including a centralized
database, support from the genetic testing laboratories, practice guidelines from a major
organization, continuing education opportunities, and functional studies.
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